Brain cancer breakthrough? new trial delivers drug straight to tumor
NCT ID NCT05271240
First seen Jun 09, 2026 · Last updated Jun 23, 2026 · Updated 4 times
Summary
This phase III trial is testing whether delivering the drug bevacizumab (Avastin) directly to the brain through a catheter, along with standard chemo and radiation, can help people with newly diagnosed glioblastoma live longer. The study will enroll 432 adults with this aggressive brain cancer. Earlier smaller studies suggested this approach might improve survival, but this larger trial will provide clearer answers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA, MALIGNANT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lenox Hill Brain Tumor Center
RECRUITINGNew York, New York, 10075, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bevacizumab (Avastin) delivered directly to the brain via a catheter
What this could lead to
If it works, this could offer a new, more effective way to treat glioblastoma, potentially extending survival beyond current standard care.
What could go wrong
This is an early phase III trial, so results are not guaranteed. The procedure carries risks from catheter use, and the drug may not improve outcomes for all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.